AB0533 EFFECT OF RENIN-ANGIOTENSIN SYSTEM INHIBITORS ON RENAL REMISSION IN LUPUS NEPHRITIS: A REAL-WORLD SINGLE-CENTER STUDY
X. Zhang,H. Huang,Y. Fan,Z. Zhang
DOI: https://doi.org/10.1136/annrheumdis-2023-eular.4162
IF: 27.973
2023-01-01
Annals of the Rheumatic Diseases
Abstract:Background Renin-angiotensin-system inhibitors (RASi) reduce urinary protein excretion and protect renal function in both diabetic and nondiabetic nephropathy. Few studies have focused on RASi in LN patients. Objectives The study aimed to provide real-world evidence to assess the effect of RASi in LN patients. Methods A total of 233 LN patients were included; 155 were RASi users, and 78 were not. The rate of proteinuria partial recovery (PPR), complete remission (CR), total remission (TR), the decline and decline rate of proteinuria at 6 and 12 months were compared by Chi-square test and Kaplan‒Meier analysis. Propensity score matching (PSM) and Cox regression analysis was performed. Results The cumulative rates of PRR, TR and CR were 133 (85.8%), 103 (66.9%), and 53 (34.2%) in the RASi group compared to 66 (87.7%), 55 (71.1%), and 44 (57.2%) in the no RASi group at 6 months, respectively. At 12 months, the cumulative rates of PRR, TR and CR were 144 (99.4%), 115 (76.1%), and 83 (56.0%) in the RASi group and 73 (97.3%), 64 (83.5%) and 54 (71.3%) in the no RASi group, respectively. There was no statistically significant difference in cumulative PRR and TR rates between the two groups (p=0.601 and 0.203). The cumulative CR rate was significantly higher in the no RASi group (p=0.001). The UTP level of the RASi group was consistently higher than that of the no RASi group at 6 [0.5(0.2,1.6) vs. 0.3(0.1,0.7), p=0.003) and 12 months [0.2(0.1,0.6) vs. 0.1(0.1,0.3), p=0.008]. However, the ΔUTP was significantly higher in the RASi group [6 months: 2.6 (1.3, 5.1) vs. 1.2 (0.8, 2.4), p=0.001; 12 months: 3.3 (1.6, 5.4) vs 1.4 (0.9, 2.9), p=0.001], and the decline rate did not reach significance. Meanwhile, the serum SCr showed no difference between the two groups. The results were similar after PSM. Only HCQ usage was a prognostic predictor of PRR (HR 2.110, 95% CI: 1.223, 3.642, p=0.007). Conclusion RASi may not benefit the renal remission of LN, and the results need to be interpreted with caution. However, RASi may help to decrease urinary protein. Further high-quality randomized controlled trials are required to evaluate the RASi effects on proteinuria and renal prognosis. References [1]Agodoa, L. Y. Appel, L. Bakris, G. L,et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial; JAMA(2001) 285,21,2719-28. [2]S. Dura´n-Barraga´n, G. McGwin Jr, et al. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus—results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (2008) 47:1093–1096. Acknowledgements: NIL. Disclosure of Interests None Declared.